Someone wrote this on a Swedish forum:
"Update:
Genovis’ share price rose by 20% in after-hours trading on the Stockholm Stock Exchange on January 31, 2025, after the company issued a press release stating that they have initiated a strategic collaboration with the global pharmaceutical company Amgen. According to the press release, Genovis will supply its innovative enzyme technologies to enhance Amgen’s biotechnology product development, particularly in antibodies and protein-based drugs.
This collaboration is highly significant as it can provide Genovis with additional revenue streams and marketing, to which the market has reacted positively. Such a partnership is considered proof of the company’s technological strength and potential in global markets."